This led Valle-León et al. (2021) to speculate that a drop in striatal ADORA2A-D2R heterodimerization may be a mechanistically relevant biomarker of schizophrenia and drugs that can facilitate the formation of ADORA2A-D2R heterodimers may possess therapeutic potential. This evidence concerns the gene DRD2 and schizophrenia.